BioSpace

Sanofi targets late-phase and commercial M&A to offset looming Dupixent decline

Focused on ensuring growth beyond Dupixent, Sanofi wants to acquire derisked assets that may benefit from the French pharma’s commercial capabilities, executives said on Friday as they reported third-quarter earnings.

By BioSpace

1 min read
Sanofi targets late-phase and commercial M&A to offset looming Dupixent decline
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights